Ftse Mib
34.127,62
-0,72%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
97.618,64
-0,60%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vistagen Therapeutics Inc (VTGN) Vistagen Therapeutics Inc (VTGN) Notizie

VTGN

Vistagen Therapeutics (VTGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VTGN
DataOraFonteTitoloSimboloCompagnia
06/12/202422:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
14/11/202422:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/11/202422:19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/11/202414:30Business WireVistagen to Present at the Stifel 2024 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/11/202422:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
07/11/202422:20Business WireVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
05/11/202414:30Business WireVistagen to Present at the 2024 Neuroscience Education Institute CongressNASDAQ:VTGNVistagen Therapeutics Inc
01/11/202413:30Business WireVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024NASDAQ:VTGNVistagen Therapeutics Inc
09/10/202414:30Business WireVistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health DayNASDAQ:VTGNVistagen Therapeutics Inc
23/09/202414:30Business WireVistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
10/09/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
13/08/202422:21Business WireVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
06/08/202414:30Business WireVistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
09/07/202414:30Business WireVistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of MigraineNASDAQ:VTGNVistagen Therapeutics Inc
27/06/202414:30Business WireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive YearNASDAQ:VTGNVistagen Therapeutics Inc
11/06/202422:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VTGNVistagen Therapeutics Inc
11/06/202422:20Business WireVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
11/06/202413:07IH Market NewsU.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices DeclineNASDAQ:VTGNVistagen Therapeutics Inc
07/06/202414:30Business WireVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024NASDAQ:VTGNVistagen Therapeutics Inc
29/05/202414:30Business WireVistagen to Present at the Jefferies Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
23/05/202414:30Business WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/05/202414:30Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
25/04/202414:30Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
09/04/202414:30Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
01/04/202414:30Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistagen Therapeutics Inc
11/03/202413:30Business WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistagen Therapeutics Inc
01/03/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistagen Therapeutics Inc
28/02/202414:30Business WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
15/02/202400:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/02/202422:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VTGN

La tua Cronologia

BIT
S24910
SG ISSUER
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network